Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
27.8M
-
Number of holders
-
126
-
Total 13F shares, excl. options
-
19.7M
-
Shares change
-
+223K
-
Total reported value, excl. options
-
$421M
-
Value change
-
-$18M
-
Put/Call ratio
-
0.5
-
Number of buys
-
73
-
Number of sells
-
-63
-
Price
-
$21.40
Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q2 2023
160 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share as of Q2 2023.
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) has 126 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.7M shares
of 27.8M outstanding shares and own 70.92% of the company stock.
Largest 10 shareholders include BlackRock Inc. (3.73M shares), ARMISTICE CAPITAL, LLC (2.04M shares), FARALLON CAPITAL MANAGEMENT LLC (1.88M shares), VANGUARD GROUP INC (1.71M shares), STATE STREET CORP (1.52M shares), BRAIDWELL LP (1.04M shares), NORTHERN TRUST CORP (975K shares), Krensavage Asset Management, LLC (688K shares), RENAISSANCE TECHNOLOGIES LLC (476K shares), and DIMENSIONAL FUND ADVISORS LP (445K shares).
This table shows the top 126 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.